Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Atumelnant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crinetics Starts Pediatric Phase 2/3 Trial For Atumelnant In CAH
    Crinetics Starts Pediatric Phase 2/3 Trial For Atumelnant In CAH

    22 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/22/3224265/0/en/Crinetics-Initiates-Phase-2-3-Pediatric-Trial-Evaluating-Atumelnant-in-Congenital-Adrenal-Hyperplasia-CAH.html

    GLOBENEWSWIRE
    22 Jan 2026
    Share Share
    Crinetics Unveils New Data, Funding as Neurocrine Rival
    Crinetics Unveils New Data, Funding as Neurocrine Rival

    07 Jan 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/crinetics-advances-potential-neurocrine-competitor-with-fresh-data-and-money

    BIOSPACE
    07 Jan 2026
    Share Share
    Crinetics Reports Strong PALSONIFY Launch, Positive CAH Data
    Crinetics Reports Strong PALSONIFY Launch, Positive CAH Data

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212693/0/en/Crinetics-Announces-Strong-PALSONIFY-Launch-Execution-and-Positive-Results-for-Concurrent-Androstenedione-Lowering-and-Glucocorticoid-Dose-Reduction-in-Phase-2-Trial-of-Atumelnant-.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Crinetics Pharma Announces PALSONIFY & Atumelnant Update
    Crinetics Pharma Announces PALSONIFY & Atumelnant Update

    04 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/04/3212404/0/en/Crinetics-Pharmaceuticals-to-Provide-PALSONIFY-Business-Update-and-Announce-Topline-Results-from-Fourth-Cohort-of-Phase-2-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia.html

    GLOBENEWSWIRE
    04 Jan 2026
    Share Share
    Crinetics Announces First Patient Dosed in Adrenal Hyperplasia
    Crinetics Announces First Patient Dosed in Adrenal Hyperplasia

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204301/0/en/Crinetics-Announces-First-Patient-Dosed-in-Pivotal-Adult-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia-CAH.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.